Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Follicular Lymphoma: early-phase trial registry
49 of 90 indexed Follicular Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #153 of 28,707 conditions by registered trial count.
90 US clinical trials · 49 currently recruiting · #153 of 28,707 conditions by registered trial count
Follicular Lymphoma: 90 US clinical trials tracked, 49 recruiting.
Follicular Lymphoma is the subject of 90 registered US clinical trials on ClinicalTrials.gov, 49 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 72 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition follicular-lymphoma
OPEN 49 | RECR 54% | LATE 7 | EARLY 72 | RANK #153 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)
Follicular Lymphoma lists 49 open slots (54% of 90 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Follicular Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Follicular Lymphoma is recruiting above its size-band peers.
49 of 90 indexed trials (54.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Follicular Lymphoma trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 4 of 90 trials (4.4%). 64 distinct sponsors appear on at least one study for this condition label.
-
Most Follicular Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 90 trials that report a genuine target (sentinel values excluded). 57 of those (63.3%) plan for fewer than 100 participants.
-
Follicular Lymphoma research is mostly interventional.
84 interventional and 6 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
90 total, page 2 of 2
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Genmab
NCT04663347
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
Hoffmann-La Roche
NCT04246086
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Merck Sharp & Dohme
NCT05458297
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT03162536
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
Xynomic Pharmaceuticals
NCT03600441
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Reid Merryman, MD
NCT05783596
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
NCT03842696
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Vaishalee Kenkre
NCT05551936
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
Synthekine
NCT05665062
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
Washington University School of Medicine
NCT05410418
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
NCT02339922
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
National Cancer Institute (NCI)
NCT03789240
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
University of Nebraska
NCT05621096
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Bio-Path Holdings
NCT04072458
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT03884998
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
H. Lee Moffitt Cancer Center and Research Institute
NCT04745559
Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma
Dana-Farber Cancer Institute
NCT03361852
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
NCT03622788
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Celgene
NCT01476787
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Pfizer
NCT02213263
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT02315612
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
Gilead Sciences
NCT01282424
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Bristol-Myers Squibb
NCT01120457
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT03833180
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
Millennium Pharmaceuticals
NCT00636792
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Millennium Pharmaceuticals
NCT00085696
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
NCT00880815
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Massachusetts General Hospital
NCT00644189
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
Ascenta Therapeutics
NCT00275431
Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL
Carevive Systems
NCT04160442
Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy
Pack Health
NCT05064787
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Masonic Cancer Center, University of Minnesota
NCT03019666
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
Emory University
NCT00634179
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co.
NCT04018248
Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma
Dana-Farber Cancer Institute
NCT00487305
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
Ascenta Therapeutics
NCT00440388
Imexon for Relapsed Follicular and Aggressive Lymphomas
University of Rochester
NCT01314014
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
National Cancer Institute (NCI)
NCT04599634
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Massachusetts General Hospital
NCT06004167
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TCR2 Therapeutics
NCT04323657
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 45 |
| Phase 2 | 27 |
| Phase 3 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Follicular Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Follicular Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Follicular Lymphoma page
90 registered trials, 49 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 49 Follicular Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Follicular Lymphoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Follicular Lymphoma condition card totals 90 registered trials; most-linked intervention Cyclophosphamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.